A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy

R. M. Diaz, A. Bateman, L. Emiliusen, A. Fielding, D. Trono, Stephen J Russell, Richard Geoffrey Vile

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The gibbon ape leukaemia virus envelope fusogenic membrane glycoprotein (GALV FMG) is a highly potent cytotoxic gene with great potential for use in cancer gene therapy. Here, we show that production of a VSV-G pseudotyped lentiviral vector expressing GALV FMG reconciles the requirements of viral production with the cytotoxic effects of GALV in human cells and has high titres on both dividing and quiescent tumour cells. Direct intratumoral injection of these stocks eradicated progressively growing human tumour xenografts. The potent bystander effect of the FMG transgene is a major contributor to the success of this approach but immunological activation may also be a factor. To our knowledge, this is the first demonstration in vivo of the potential both of FMG and lentiviral vectors for cancer gene therapy and highlights the importance of exploring different vector systems to complement the biological properties of the therapeutic transgene.

Original languageEnglish (US)
Pages (from-to)1656-1663
Number of pages8
JournalGene Therapy
Volume7
Issue number19
StatePublished - 2000

Fingerprint

Gibbon ape leukemia virus
Neoplasm Genes
Genetic Therapy
Glycoproteins
Membrane Glycoproteins
Transgenes
Bystander Effect
Heterografts
Neoplasms
Injections
Genes
Therapeutics

Keywords

  • Cancer
  • Fusogenic proteins
  • Lentiviral Vectors
  • Suicide genes

ASJC Scopus subject areas

  • Genetics

Cite this

Diaz, R. M., Bateman, A., Emiliusen, L., Fielding, A., Trono, D., Russell, S. J., & Vile, R. G. (2000). A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Therapy, 7(19), 1656-1663.

A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. / Diaz, R. M.; Bateman, A.; Emiliusen, L.; Fielding, A.; Trono, D.; Russell, Stephen J; Vile, Richard Geoffrey.

In: Gene Therapy, Vol. 7, No. 19, 2000, p. 1656-1663.

Research output: Contribution to journalArticle

Diaz, RM, Bateman, A, Emiliusen, L, Fielding, A, Trono, D, Russell, SJ & Vile, RG 2000, 'A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy', Gene Therapy, vol. 7, no. 19, pp. 1656-1663.
Diaz RM, Bateman A, Emiliusen L, Fielding A, Trono D, Russell SJ et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Therapy. 2000;7(19):1656-1663.
Diaz, R. M. ; Bateman, A. ; Emiliusen, L. ; Fielding, A. ; Trono, D. ; Russell, Stephen J ; Vile, Richard Geoffrey. / A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. In: Gene Therapy. 2000 ; Vol. 7, No. 19. pp. 1656-1663.
@article{00d5ced8a825426baa6f23c3633bf818,
title = "A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy",
abstract = "The gibbon ape leukaemia virus envelope fusogenic membrane glycoprotein (GALV FMG) is a highly potent cytotoxic gene with great potential for use in cancer gene therapy. Here, we show that production of a VSV-G pseudotyped lentiviral vector expressing GALV FMG reconciles the requirements of viral production with the cytotoxic effects of GALV in human cells and has high titres on both dividing and quiescent tumour cells. Direct intratumoral injection of these stocks eradicated progressively growing human tumour xenografts. The potent bystander effect of the FMG transgene is a major contributor to the success of this approach but immunological activation may also be a factor. To our knowledge, this is the first demonstration in vivo of the potential both of FMG and lentiviral vectors for cancer gene therapy and highlights the importance of exploring different vector systems to complement the biological properties of the therapeutic transgene.",
keywords = "Cancer, Fusogenic proteins, Lentiviral Vectors, Suicide genes",
author = "Diaz, {R. M.} and A. Bateman and L. Emiliusen and A. Fielding and D. Trono and Russell, {Stephen J} and Vile, {Richard Geoffrey}",
year = "2000",
language = "English (US)",
volume = "7",
pages = "1656--1663",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "19",

}

TY - JOUR

T1 - A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy

AU - Diaz, R. M.

AU - Bateman, A.

AU - Emiliusen, L.

AU - Fielding, A.

AU - Trono, D.

AU - Russell, Stephen J

AU - Vile, Richard Geoffrey

PY - 2000

Y1 - 2000

N2 - The gibbon ape leukaemia virus envelope fusogenic membrane glycoprotein (GALV FMG) is a highly potent cytotoxic gene with great potential for use in cancer gene therapy. Here, we show that production of a VSV-G pseudotyped lentiviral vector expressing GALV FMG reconciles the requirements of viral production with the cytotoxic effects of GALV in human cells and has high titres on both dividing and quiescent tumour cells. Direct intratumoral injection of these stocks eradicated progressively growing human tumour xenografts. The potent bystander effect of the FMG transgene is a major contributor to the success of this approach but immunological activation may also be a factor. To our knowledge, this is the first demonstration in vivo of the potential both of FMG and lentiviral vectors for cancer gene therapy and highlights the importance of exploring different vector systems to complement the biological properties of the therapeutic transgene.

AB - The gibbon ape leukaemia virus envelope fusogenic membrane glycoprotein (GALV FMG) is a highly potent cytotoxic gene with great potential for use in cancer gene therapy. Here, we show that production of a VSV-G pseudotyped lentiviral vector expressing GALV FMG reconciles the requirements of viral production with the cytotoxic effects of GALV in human cells and has high titres on both dividing and quiescent tumour cells. Direct intratumoral injection of these stocks eradicated progressively growing human tumour xenografts. The potent bystander effect of the FMG transgene is a major contributor to the success of this approach but immunological activation may also be a factor. To our knowledge, this is the first demonstration in vivo of the potential both of FMG and lentiviral vectors for cancer gene therapy and highlights the importance of exploring different vector systems to complement the biological properties of the therapeutic transgene.

KW - Cancer

KW - Fusogenic proteins

KW - Lentiviral Vectors

KW - Suicide genes

UR - http://www.scopus.com/inward/record.url?scp=0033759150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033759150&partnerID=8YFLogxK

M3 - Article

C2 - 11083474

AN - SCOPUS:0033759150

VL - 7

SP - 1656

EP - 1663

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 19

ER -